BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37600705)

  • 21. Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan.
    Akatani N; Wakabayashi H; Kayano D; Inaki A; Takata A; Hiromasa T; Yamase T; Kunita Y; Watanabe S; Mori H; Saito S; Nakajima K; Kinuya S
    Endocr J; 2023 Mar; 70(3):315-322. PubMed ID: 36567077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer.
    Liu L; Zhang X; Tian T; Huang R; Liu B
    Thyroid; 2020 Jul; 30(7):1017-1024. PubMed ID: 31964278
    [No Abstract]   [Full Text] [Related]  

  • 23. Is radioiodine ablation with 1.1 GBq (30 mCi)
    Ilera V; Califano I; Cavallo A; Faure E; Vázquez A; Pitoia F;
    Endocrine; 2023 Jun; 80(3):606-611. PubMed ID: 36988853
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric Thyroid Cancer: Postoperative Classifications and Response to Initial Therapy as Prognostic Factors.
    Lazar L; Lebenthal Y; Segal K; Steinmetz A; Strenov Y; Cohen M; Yaniv I; Yackobovitch-Gavan M; Phillip M
    J Clin Endocrinol Metab; 2016 May; 101(5):1970-9. PubMed ID: 26930182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
    Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
    Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography.
    Rodriguez JD; Kirk D; Benefield T; Maygarden SJ; Pou K; Kim LT; Hackman TG; Khandani AH
    Nucl Med Commun; 2020 Mar; 41(3):228-234. PubMed ID: 31895755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial.
    Qu Y; Huang R; Li L
    Ann Nucl Med; 2017 Jan; 31(1):71-83. PubMed ID: 27757803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
    Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
    Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan.
    Saghari M; Gholamrezanezhad A; Mirpour S; Eftekhari M; Takavar A; Fard-Esfahani A; Fallahi B; Beiki D
    Nucl Med Commun; 2006 Jul; 27(7):567-72. PubMed ID: 16794517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance in diagnosing patients with conflicting observational data for post surgery radioiodinated ablation of thyroid remnants.
    Simsek FS; Balci TA; Dönder Y; Ugur K; Kilinc F; Cetinkaya Z; Ustundag B; Ozercan IH; Elmali F
    Hell J Nucl Med; 2019; 22(1):58-63. PubMed ID: 30843011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fractionated dosage of radioiodine for the ablation of differentiated thyroid carcinoma.
    Czepczyński R; Ziemnicka K; Baczyk M; Oleksa R; Ruchała M; Sowiński J
    Thyroid; 2005 Nov; 15(11):1261-5. PubMed ID: 16356090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
    Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
    Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative remnant
    Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
    Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake.
    Gaertner FC; Okamoto S; Shiga T; Ito YM; Uchiyama Y; Manabe O; Hattori N; Tamaki N
    Clin Nucl Med; 2015 May; 40(5):378-83. PubMed ID: 25608175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
    Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
    J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.
    Zhao T; Liang J; Guo Z; Li T; Lin Y
    Clin Nucl Med; 2016 Jun; 41(6):454-8. PubMed ID: 26914559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.